Patents by Inventor Randall T. Peterson

Randall T. Peterson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240287609
    Abstract: Disclosed herein are droplets comprising gene editing systems and barcodes. The disclosure further relates to methods for large-scale identification of genes in vivo using barcodes and methods for large-scale identification of gene function in a plurality of subjects using a plurality of droplets.
    Type: Application
    Filed: June 8, 2022
    Publication date: August 29, 2024
    Inventors: Saba Parvez, Randall T. Peterson, Jing-Ruey Joanna Yeh
  • Patent number: 11396516
    Abstract: The present application provides tricyclic compounds useful, e.g., in treating or preventing cardiotoxicity and cardiomyopathy in patients undergoing cardiotoxic chemotherapy. Methods of making and using the tricyclic compounds to treat cancer are also described.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: July 26, 2022
    Assignee: The General Hospital Corporation
    Inventors: Randall T. Peterson, Aarti Asnani, Yan Liu, Baohui Zheng, You Wang
  • Publication number: 20210163495
    Abstract: The present application provides tricyclic compounds useful, e.g., in treating or preventing cardiotoxicity and cardiomyopathy in patients undergoing cardiotoxic chemotherapy. Methods of making and using the tricyclic compounds to treat cancer are also described.
    Type: Application
    Filed: June 15, 2018
    Publication date: June 3, 2021
    Inventors: Randall T. Peterson, Aarti Asnani, Yan Liu, Baohui Zheng, You Wang
  • Publication number: 20200312426
    Abstract: Embodiments of the present invention provide materials and methods for performing phenotype-based chemical screens. Embodiments disclosed herein pertain to the use of a battery of high-throughput zebrafish behavioral assays to generate behavioral profiles. In accordance with these embodiments, responses to various chemical compounds with known and unknown biological functions can be used to generate behavioral profiles. Embodiments also involve generating behavioral profiles based on genetic mutations or environmental perturbations. Establishing databases of behavioral profiles facilitates identification of novel chemicals that phenocopy effects of therapeutic agents and/or that modulate genetic or environmental behavioral profiles, thereby providing a basis for not only assessing the properties of known chemical compounds but also for developing novel treatments for human diseases.
    Type: Application
    Filed: March 6, 2020
    Publication date: October 1, 2020
    Applicants: NemaMetrix, Inc, The General Hospital Corportation, dba Massachusetts General Hospital
    Inventors: David Kokel, Randall T. Peterson, Giancarlo Bruni, Andrea Velenich
  • Publication number: 20190337956
    Abstract: The invention described herein relates generally to neuroactive compounds and compositions for the treatment psychotic disorders, methods for treating psychosis using these neuroactive compounds, and methods for screening for novel neuroactive compounds. Certain aspects are directed to a family of compounds called “finazines.” Certain aspects are directed to in vivo screening methods using high-throughput behavioral assays in zebrafish.
    Type: Application
    Filed: April 9, 2019
    Publication date: November 7, 2019
    Applicant: The General Hospita Corporation
    Inventors: Randall T. Peterson, Andrew J. Rennekamp, David Kokel, You Wang
  • Patent number: 10301318
    Abstract: The invention described herein relates generally to neuroactive compounds and compositions for the treatment psychotic disorders, methods for treating psychosis using these neuroactive compounds, and methods for screening for novel neuroactive compounds. Certain aspects are directed to a family of compounds called “finazines.” Certain aspects are directed to in vivo screening methods using high-through-put behavioral assays in zebrafish.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: May 28, 2019
    Assignee: The General Hospital Corporation
    Inventors: Randall T. Peterson, Andrew J. Rennekamp, David Kokel, You Wang
  • Publication number: 20180161310
    Abstract: Compounds that inhibit synaptic hyperexcitability, pharmaceutical compositions of these compounds, and methods of using the compounds and pharmaceutical compositions thereof to treat diseases and/or disorders such as epilepsy, neuropathic pain, spinal cord injury spasticity, morphine-induced hyperalgesia, schizophrenia, and autism spectrum disorders are disclosed.
    Type: Application
    Filed: December 7, 2017
    Publication date: June 14, 2018
    Inventors: Randall T. Peterson, David Kokel, Tama Evron, Andrea Velenich
  • Publication number: 20170247383
    Abstract: The invention described herein relates generally to neuroactive compounds and compositions for the treatment psychotic disorders, methods for treating psychosis using these neuroactive compounds, and methods for screening for novel neuroactive compounds. Certain aspects are directed to a family of compounds called “finazines.” Certain aspects are directed to in vivo screening methods using high-through-put behavioral assays in zebrafish.
    Type: Application
    Filed: June 25, 2015
    Publication date: August 31, 2017
    Applicant: THE GENERAL HOSPITAL CORPORATION
    Inventors: Randall T. PETERSON, Andrew J. RENNEKAMP, David KOKEL, You WANG
  • Publication number: 20170169164
    Abstract: Embodiments of the present invention provide materials and methods for performing phenotype-based chemical screens. Embodiments disclosed herein pertain to the use of a battery of high-throughput zebrafish behavioral assays to generate behavioral profiles. In accordance with these embodiments, responses to various chemical compounds with known and unknown biological functions can be used to generate behavioral profiles. Embodiments also involve generating behavioral profiles based on genetic mutations or environmental perturbations. Establishing databases of behavioral profiles facilitates identification of novel chemicals that phenocopy effects of therapeutic agents and/or that modulate genetic or environmental behavioral profiles, thereby providing a basis for not only assessing the properties of known chemical compounds but also for developing novel treatments for human diseases.
    Type: Application
    Filed: October 27, 2016
    Publication date: June 15, 2017
    Inventors: David Kokel, Randall T. Peterson, Giancarlo Bruni, Andrea Velenich
  • Publication number: 20170079252
    Abstract: Provided herein are methods of sterilizing fish by contacting an embryonic or juvenile fish with a compound of formula (I). In some embodiments, the compound is primordazine or a derivative thereof.
    Type: Application
    Filed: December 1, 2016
    Publication date: March 23, 2017
    Applicant: THE GENERAL HOSPITAL CORPORATION
    Inventors: Randall T. Peterson, Peter J. Schlueter
  • Patent number: 9538734
    Abstract: Provided herein are methods of sterilizing fish by contacting an embryonic or juvenile fish with a compound of formula (I). In some embodiments, the compound is primordazine or a derivative thereof.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: January 10, 2017
    Assignee: THE GENERAL HOSPITAL CORPORATION
    Inventors: Randall T. Peterson, Peter J. Schlueter
  • Publication number: 20160115167
    Abstract: The present invention provides small molecule inhibitors of BMP signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds may also be used to reduce circulating levels of ApoB-100 or LDL and treat or prevent acquired or congenital hypercholesterolemia or hyperlipoproteinemia; diseases, disorders, or syndromes associated with defects in lipid absorption or metabolism; or diseases, disorders, or syndromes caused by hyperlipidemia.
    Type: Application
    Filed: March 4, 2014
    Publication date: April 28, 2016
    Inventors: Paul B. Yu, Gregory D. Cuny, Agustin H. Mohedas, Kenneth D. Bloch, Randall T. Peterson
  • Publication number: 20150150843
    Abstract: The invention provides a method of reducing anthracycline-induced cardiotoxicity by administering a toxicity-reducing compound, such as a compound of Formulas (I), (II) or (III) or a combination thereof, and/or diphenyl urea (DPU), dexrazoxane (DEX), to a patient receiving an anthracycline. The invention also provides a method of identifying toxicity-reducing compounds.
    Type: Application
    Filed: May 16, 2013
    Publication date: June 4, 2015
    Inventors: Randall T. Peterson, Yan Liu
  • Patent number: 9045484
    Abstract: The present invention provides pyridinyl-substituted pyrazolyl pyrimidine small molecule inhibitors of bone morphogenetic protein (BMP) signaling having the structure of formula (I), wherein variables A, B, E, F, X, Y, Z, Ar, L1, R4 and R15 are as defined in the specification. The compounds of the invention are useful in modulating cell growth, differentiation, proliferation, and apoptosis, and thus are useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation.
    Type: Grant
    Filed: July 12, 2013
    Date of Patent: June 2, 2015
    Assignees: The Brigham and Women's Hospital, Inc., The General Hospital Corporation
    Inventors: Paul B. Yu, Gregory D. Cuny, Kenneth D. Bloch, Randall T. Peterson, Charles C. Hong
  • Publication number: 20140261212
    Abstract: Provided herein are methods of sterilizing fish by contacting an embryonic or juvenile fish with a compound of formula (I). In some embodiments, the compound is primordazine or a derivative thereof.
    Type: Application
    Filed: March 12, 2014
    Publication date: September 18, 2014
    Applicant: THE GENERAL HOSPITAL CORPORATION
    Inventors: Randall T. PETERSON, Peter J. SCHLUETER
  • Publication number: 20140011805
    Abstract: The present invention provides small molecule inhibitors of BMP signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation.
    Type: Application
    Filed: July 12, 2013
    Publication date: January 9, 2014
    Inventors: Paul B. Yu, Gregory D. Cuny, Kenneth D. Bloch, Randall T. Peterson, Charles C. Hong
  • Patent number: 8507501
    Abstract: The present invention provides small molecule inhibitors of BMP signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation.
    Type: Grant
    Filed: March 13, 2009
    Date of Patent: August 13, 2013
    Assignees: The Brigham and Women's Hospital, Inc., The General Hospital Corporation
    Inventors: Paul B. Yu, Gregory D. Cuny, Kenneth D. Bloch, Randall T. Peterson, Charles C. Hong
  • Publication number: 20110053930
    Abstract: The present invention provides small molecule inhibitors of BMP signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation.
    Type: Application
    Filed: March 13, 2009
    Publication date: March 3, 2011
    Applicants: The Brigham and Women's Hospital, Inc., The General Hospital Corporation
    Inventors: Paul B. Yu, Gregory D. Cuny, Kenneth D. Bloch, Randall T. Peterson, Charles C. Hong
  • Publication number: 20100093760
    Abstract: The invention provides methods for identifying compounds that modulate cell signaling, as well as therapeutic methods that employ such compounds.
    Type: Application
    Filed: September 12, 2007
    Publication date: April 15, 2010
    Applicant: The General Hospital Corporation
    Inventors: Paul B. Yu, Charles C. Hong, Kenneth D. Bloch, Randall T. Peterson
  • Publication number: 20080199449
    Abstract: The invention includes methods and compositions for use in treating or preventing vascular disease or promoting vascular growth or development. The methods and compositions can be used, for example, in the treatment of diseases associated with ischemia, such as heart attack and stroke.
    Type: Application
    Filed: August 11, 2006
    Publication date: August 21, 2008
    Applicant: The General Hospital Corporation
    Inventors: Randall T. Peterson, Charles C. Hong